Deal Watch: After Novartis Deal, GSK Increases Vaccine Emphasis With GlycoVaxyn Buyout

Sanofi moves into ROR gamma T R&D for potential autoimmune therapies in collaboration with Lead Pharma, while Intrexon acquires Belgium’s ActoGeniX and its platform technology for creating a novel class of biotherapeutics targeting the oral and GI tracts. Teva heads off dispute with Eagle, bringing in new bendamustine formulation.

More from Archive

More from Pink Sheet